Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis.
Adenocarcinoma
/ pathology
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Austria
Chemoradiotherapy, Adjuvant
/ mortality
Combined Modality Therapy
Esophageal Neoplasms
/ pathology
Esophagectomy
/ mortality
Female
Follow-Up Studies
Humans
Male
Middle Aged
Perioperative Care
/ mortality
Prognosis
Retrospective Studies
Survival Rate
Adenocarcinoma
Chemoradiation
Chemotherapy
Esophagectomy
Esophagus
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
19 Aug 2019
19 Aug 2019
Historique:
received:
20
05
2019
accepted:
13
08
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
8
2
2020
Statut:
epublish
Résumé
The aim of this study was to compare the outcome of patients with adenocarcinoma of the distal esophagus (AEG type I) treated with neoadjuvant chemoradiation or perioperative chemotherapy. Eligible patients from four Austrian centers were selected to conduct a retrospective analysis. All patients treated between January 2007 and October 2017 with chemotherapy according to EOX-protocol (Epirubicin, Oxaliplatin, Xeloda) or chemoradiation according to CROSS-protocol (carboplatin/paclitaxel + RTX 41.4 Gy), before esophagectomy were included. Primary outcomes disease-free survival (DFS) and overall survival (OS) as well as secondary outcomes downstaging of T- or N-stage and achievement of pathological complete response pCR (ypT0N0M0) were analyzed. Data of 119 patients were included. Complete data was available in 104 patients, 53 patients in the chemoradiation group and 51 patients in the chemotherapy group. The mean number of lymph nodes removed was significantly higher in the EOX group (EOX 29 ± 15.5 vs. CROSS 22 ± 8.8; p < 0.05). Median follow-up in the CROSS group was 17 months (CI 95% 8.8-25.2) and in the EOX group 37 months (CI 95% 26.5-47.5). In the chemotherapy group, the OS rate after half a year, - 1, and 3 years was 92%, 75%, and 51%. After chemoradiation, overall survival after half a year was 85 %, after 1 year 66%, and after 3 years 17%. In the EOX group DFS after ½, - 1, and 3 years was 90%, 73%, and 45%, in the chemoradiation group after half a year 81%, after 1 year 55% and after 3 years 15%. Pathological complete response (pCR) was achieved in 23% of patients after CROSS and in 10% after EOX (p < 0.000). There seem to be clear advantages for chemoradiation, concerning the major response of the primary tumor, whereas a tendency in favor for chemotherapy is seen in regards to systemic tumor control. Furthermore, the type of neoadjuvant treatment has a significant influence on the number of lymph nodes resected.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to compare the outcome of patients with adenocarcinoma of the distal esophagus (AEG type I) treated with neoadjuvant chemoradiation or perioperative chemotherapy.
METHODS
METHODS
Eligible patients from four Austrian centers were selected to conduct a retrospective analysis. All patients treated between January 2007 and October 2017 with chemotherapy according to EOX-protocol (Epirubicin, Oxaliplatin, Xeloda) or chemoradiation according to CROSS-protocol (carboplatin/paclitaxel + RTX 41.4 Gy), before esophagectomy were included. Primary outcomes disease-free survival (DFS) and overall survival (OS) as well as secondary outcomes downstaging of T- or N-stage and achievement of pathological complete response pCR (ypT0N0M0) were analyzed. Data of 119 patients were included.
RESULTS
RESULTS
Complete data was available in 104 patients, 53 patients in the chemoradiation group and 51 patients in the chemotherapy group. The mean number of lymph nodes removed was significantly higher in the EOX group (EOX 29 ± 15.5 vs. CROSS 22 ± 8.8; p < 0.05). Median follow-up in the CROSS group was 17 months (CI 95% 8.8-25.2) and in the EOX group 37 months (CI 95% 26.5-47.5). In the chemotherapy group, the OS rate after half a year, - 1, and 3 years was 92%, 75%, and 51%. After chemoradiation, overall survival after half a year was 85 %, after 1 year 66%, and after 3 years 17%. In the EOX group DFS after ½, - 1, and 3 years was 90%, 73%, and 45%, in the chemoradiation group after half a year 81%, after 1 year 55% and after 3 years 15%. Pathological complete response (pCR) was achieved in 23% of patients after CROSS and in 10% after EOX (p < 0.000).
CONCLUSIONS
CONCLUSIONS
There seem to be clear advantages for chemoradiation, concerning the major response of the primary tumor, whereas a tendency in favor for chemotherapy is seen in regards to systemic tumor control. Furthermore, the type of neoadjuvant treatment has a significant influence on the number of lymph nodes resected.
Identifiants
pubmed: 31426805
doi: 10.1186/s12957-019-1693-6
pii: 10.1186/s12957-019-1693-6
pmc: PMC6701048
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Références
Cancer. 2001 Aug 1;92(3):549-55
pubmed: 11505399
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
Ann Surg. 2008 Oct;248(4):549-56
pubmed: 18936567
Br J Cancer. 2009 Jun 2;100(11):1725-30
pubmed: 19436301
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Eur J Cancer. 2012 Nov;48(16):2941-53
pubmed: 22921186
Br J Cancer. 2013 Feb 19;108(3):519-26
pubmed: 23322206
Eur J Cancer. 2013 Oct;49(15):3149-58
pubmed: 23800671
Br J Surg. 2014 Mar;101(4):321-38
pubmed: 24493117
Lancet Oncol. 2015 Jan;16(1):e23-31
pubmed: 25638550
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Med Oncol. 2016 Jul;33(7):62
pubmed: 27225939
BMC Cancer. 2016 Jul 19;16:503
pubmed: 27435280
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
J Surg Oncol. 2017 Jun;115(7):812-820
pubmed: 28267212
Ann Cardiothorac Surg. 2017 Mar;6(2):119-130
pubmed: 28447000
BMC Cancer. 2017 Jun 3;17(1):401
pubmed: 28578652
Eur J Surg Oncol. 2017 Aug;43(8):1572-1580
pubmed: 28666624
Sci Rep. 2018 Jan 11;8(1):446
pubmed: 29323261
Dis Esophagus. 2019 Feb 1;32(2):null
pubmed: 30137281
Ann N Y Acad Sci. 2018 Dec;1434(1):132-138
pubmed: 30138540
Chirurg. 1987 Jan;58(1):25-32
pubmed: 3829805